teaser
Bevacizumab (Avastin®) has been launched in the UK for first-linetreatment of metastatic breast cancer in combination with paclitaxel.The drug is already licensed for treating metastatic bowel cancer.Approval was based on a phase III trial in 722 women with locallyrecurrent or metastatic breast cancer, randomised to receive treatmentwith paclitaxel with or without bevacizumab. According to manufacturerRoche, patients on the combination had a median progression-freesurvival of 13.3 months vs 6.7 months in the paclitaxel group. Thecompany will submit overall survival data analysis to EU regulatoryauthorities during 2007.
New Electronic Library for Medicines 10/5/2007
